Arena Pharma (ARNA) Prices 5.5M Share Common Offering at $50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
After-Hours Stock Movers 05/27: (PHAS) (SMTC) (TOL) Higher; (IOVA) (ARNA) (PLT) Lower (more...)
May 27, 2020 5:41 PM EDTToday's After-Hours Stock Movers:
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) 74.4% HIGHER; announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).
Semtech (NASDAQ: SMTC) 13.6% HIGHER; reported Q1 EPS of $0.35, $0.03 better than the analyst estimate of $0.32. Revenue for the quarter came in at $132.7 million versus the consensus estimate of $129.28 million. Semtech sees Q2 2021 EPS of... More
Arena Pharma (ARNA) Announces $250M Proposed Public Offering of Common Stock
May 27, 2020 4:01 PM EDTArena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $250,000,000 of its common stock. All of the shares are being offered by Arena. In addition, Arena intends... More
Arena Pharma (ARNA) Reports Complete Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis; Provides Program Updates
May 26, 2020 8:34 AM EDTArena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has completed full enrollment of the Phase 2b ADVISE trial evaluating etrasimod, an investigational next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator, for the potential treatment of moderate-to-severe atopic dermatitis. The trial enrolled 140 patients at study sites across the United States, Canada and Australia, with a primary efficacy... More
